Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: John Bloxom who wrote (7657)	5/12/1999 10:44:00 AM
From: John McDonald	Respond to of 9523

Dream on John...people are way too lazy when all they have to do is swallow a pill.

To: John Bloxom who wrote (7657)	5/12/1999 10:46:00 AM
From: Nick	Read Replies (1) \| Respond to of 9523

Pfizer, Neurogen extend obesity research program BRANFORD, Conn. May 12 (Reuters) - Pfizer Inc. (PFE - news) has extended its collaboration with Neurogen Corp. (NRGN - news) to develop anti-obesity drugs which block a potent neurotransmitter that stimulates eating, Neurogen said Wednesday. The one-year extension of the research program will fund Neurogen's efforts to discover new drugs through October 2000 that block the neuropeptide Y (NPY) neurotransmitter. The NPY antagonists that Neurogen and Pfizer have been developing since their collaboration began in November 1995 have been shown to reduce food intake and weight gain in animals. Neurogen and Pfizer are also working together in three other human drug development programs, which focus on treating anxiety/depression, insomnia and dementia. In April, Roche Holding AG won U.S. Food and Drug Administration approval to market its anti-obesity drug, Xenical, which hinders the body's ability to absorb fat.